| Objective: | Compare PCI with TAXUS® Express2™ stent vs. CABG in patients with de novo three-vessel disease (3VD) or left main (LM) disease (isolated or in combination with 1, 2, or 3VD) |
| Stent: | TAXUS Express2 |
| Purpose: | Demonstrate non-inferiority of TAXUS Express2 PCI vs. CABG for 3VD or LM |
| Design: | Prospective, multicenter clinical trial with all-comers design. Randomized for those patients deemed eligible for both PCI and CABG. Nested registries (CABG only or PCI only) for patients judged suitable for only one treatment modality. |
| Lesion: | de novo three-vessel disease (3VD) or left main (LM) disease (isolated or in combination with 1, 2, or 3VD) |
| Control: | Coronary artery bypass graft (CABG) surgery |
| Release Kinetics: | Slow Release (SR) |
| Primary Endpoint: | 1-year MACCE rate (death, MI, repeat PCI, stroke) |
| Location and Sites: | Europe and United States, 81 sites |
| Status: | Enrolling |
| Number of Patients: | Up to 4600 (1800 randomized) planned |
| Principal Investigators: | Patrick Serruys, MD, Thoraxcenter-Erasmus, Rotterdam Friedrich Mohr, MD, University of Leipzig, Germany |
